Medrx Co

Medrx Co Net Debt / EBITDA

The Net Debt to EBITDA of Medrx Co (4586.T) as of Oct 17, 2026 is 0.90. In the previous year, Net Debt to EBITDA was 1.61 — a change of -44.15% (lower).

Net Debt / EBITDA

0.90

YoY

-44.15%

Last updated:

Net Debt to EBITDA of Medrx Co is 2022 0.90 . Net Debt to EBITDA of Medrx Co was 2021 1.61 . It decreases by -44.15% lower compared to the previous year.

The Medrx Co Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2013
12.85 JPY
Jan 1, 2016
1.68 JPY
Jan 1, 2017
1.71 JPY
Jan 1, 2018
1.41 JPY
Jan 1, 2019
0.87 JPY
Jan 1, 2020
1.56 JPY
Jan 1, 2021
1.61 JPY
Jan 1, 2022
0.90 JPY
The Medrx Co Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
0.90-44.15%
1.61+2.99%
1.56+80.13%
0.87-38.62%
1.41-17.41%
1.71+2.18%
1.68-86.96%
12.85+1,286.94%
0.93-66.73%
2.79+28.05%
2.18+82.09%
1.19-69.67%
3.94—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co Ltd is a pharmaceutical company based in Higashikagawa-shi, Japan, operating within the Health Care sector. The company has 22 employees and went public on February 13, 2013, with its ticker listed as 4586.T on the Tokyo Stock Exchange. Medrx focuses on pharmaceutical drug development utilizing transdermal absorption technology. The company's website is www.medrx.co.jp. Medrx develops new medicines using percutaneous absorption formulation technology, specifically employing ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). These technologies leverage ionic liquid characteristics and nano colloidization to enhance drug efficacy, minimize side effects, and provide alternative administration methods for patients who cannot take medications orally. The company aims to create medicines with innovative value by addressing challenges such as patient compliance and delivery methods for difficult-to-administer drugs. Medrx is headquartered in Higashikagawa-shi, Kagawa Prefecture, and maintains a small operational scale with a dedicated team of 22 full-time employees. The company's business model centers on developing pharmaceuticals that improve patient outcomes through advanced transdermal delivery systems, targeting specific medical needs where traditional oral administration is impractical or ineffective. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Net Debt to EBITDA of Medrx Co is 0.90 in 2022.

Net Debt to EBITDA of Medrx Co changed from 1.61 to 0.90, representing a -44.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Medrx Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Medrx Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Medrx Co

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Medrx Co